{"log_id": 6275693129300576396, "direction": 0, "words_result_num": 27, "words_result": [{"probability": {"variance": 0.000714, "average": 0.979694, "min": 0.91654}, "location": {"width": 138, "top": 239, "height": 25, "left": 178}, "words": "CYP2C8抑制。"}, {"probability": {"variance": 0.002894, "average": 0.976044, "min": 0.735271}, "location": {"width": 801, "top": 278, "height": 45, "left": 221}, "words": "人肝细胞的体外研究还表明阿昔替尼不诱导 CYPIA1、CYP1A2或CYP3A4/5。因"}, {"probability": {"variance": 0.000594, "average": 0.988092, "min": 0.903118}, "location": {"width": 847, "top": 334, "height": 45, "left": 176}, "words": "此预期阿昔替尼联合用药不会降低合用的CYP1A1、 CYPIA2或CYP3A4/5底物的体内"}, {"probability": {"variance": 3e-06, "average": 0.99891, "min": 0.995976}, "location": {"width": 91, "top": 404, "height": 28, "left": 179}, "words": "血浆浓度"}, {"probability": {"variance": 0.011893, "average": 0.961617, "min": 0.634618}, "location": {"width": 210, "top": 454, "height": 35, "left": 177}, "words": "P-糖蛋白的体外研究"}, {"probability": {"variance": 0.000212, "average": 0.994704, "min": 0.935412}, "location": {"width": 802, "top": 496, "height": 46, "left": 225}, "words": "体外研究表明阿昔替尼抑制P糖蛋白。然而,预期在治疗血浆浓度下阿昔替尼不"}, {"probability": {"variance": 0.000997, "average": 0.991772, "min": 0.806995}, "location": {"width": 846, "top": 551, "height": 48, "left": 180}, "words": "会抑制P糖蛋白。因此预期阿昔替尼联合用药不会增加体内地高辛或其它P糖蛋白底"}, {"probability": {"variance": 3.1e-05, "average": 0.996248, "min": 0.984152}, "location": {"width": 134, "top": 622, "height": 28, "left": 182}, "words": "物的血浆浓度"}, {"probability": {"variance": 5e-06, "average": 0.997703, "min": 0.993066}, "location": {"width": 123, "top": 673, "height": 30, "left": 187}, "words": "【药物过量】"}, {"probability": {"variance": 1e-06, "average": 0.999353, "min": 0.996858}, "location": {"width": 340, "top": 723, "height": 36, "left": 226}, "words": "尚无针对阿昔替尼药物过量的治疗"}, {"probability": {"variance": 0, "average": 0.770625, "min": 0.770625}, "location": {"width": 54, "top": 665, "height": 121, "left": 997}, "words": "演"}, {"probability": {"variance": 8.2e-05, "average": 0.995885, "min": 0.959687}, "location": {"width": 808, "top": 766, "height": 49, "left": 226}, "words": "在接受阿昔替尼治疗的RCC患者的一项对照临床研究中,有1例患者意外接受"}, {"probability": {"variance": 0.000342, "average": 0.994032, "min": 0.904529}, "location": {"width": 544, "top": 827, "height": 44, "left": 181}, "words": "20mg剂量,每日两次持续治疗4天,出现头晕(1级)"}, {"probability": {"variance": 0.003752, "average": 0.780632, "min": 0.71938}, "location": {"width": 147, "top": 798, "height": 56, "left": 882}, "words": "多不"}, {"probability": {"variance": 0.00634, "average": 0.975765, "min": 0.587079}, "location": {"width": 801, "top": 878, "height": 45, "left": 228}, "words": "在一项阿昔替尼临床剂量探索研究中,接受10 mg BID或20 mg BID起始剂量的受"}, {"probability": {"variance": 1e-05, "average": 0.997834, "min": 0.985911}, "location": {"width": 722, "top": 934, "height": 43, "left": 184}, "words": "试者发生的不良反应包括高血压、与高血压相关的癫痫发作及致死性咯血"}, {"probability": {"variance": 8e-06, "average": 0.99799, "min": 0.987844}, "location": {"width": 587, "top": 989, "height": 44, "left": 230}, "words": "在怀疑过量情况下,应停用阿昔替尼,同时给予支持性治疗"}, {"probability": {"variance": 7e-06, "average": 0.99775, "min": 0.993719}, "location": {"width": 123, "top": 1057, "height": 28, "left": 192}, "words": "【临床试验】"}, {"probability": {"variance": 0.00029, "average": 0.992125, "min": 0.929895}, "location": {"width": 264, "top": 1107, "height": 36, "left": 186}, "words": "A406032研究(全球研究)"}, {"probability": {"variance": 3.3e-05, "average": 0.997925, "min": 0.966688}, "location": {"width": 801, "top": 1150, "height": 46, "left": 232}, "words": "该研究为一项随机、开放、全球范围的多中心3期研究,评价了阿昔替尼的安全性"}, {"probability": {"variance": 7e-06, "average": 0.998686, "min": 0.987376}, "location": {"width": 845, "top": 1205, "height": 48, "left": 190}, "words": "和有效性。将既往接受一种全身治疗方案(包括含舒尼替尼、贝伐单抗、替西罗莫司或"}, {"probability": {"variance": 0.000114, "average": 0.994541, "min": 0.957596}, "location": {"width": 845, "top": 1260, "height": 48, "left": 189}, "words": "细胞因子的方案)治疗过程中或治疗后疾病进展的晚期RCC患者(N=723)随机分组"}, {"probability": {"variance": 0.002249, "average": 0.988637, "min": 0.684438}, "location": {"width": 829, "top": 1315, "height": 49, "left": 206}, "words": "1:1)接受阿昔替尼(N=361)或索拉非尼(N=362)。由盲态独立中心审查委员会评"}, {"probability": {"variance": 0.010187, "average": 0.969503, "min": 0.450409}, "location": {"width": 829, "top": 1371, "height": 49, "left": 190}, "words": "估主要终点无进展生存期(PFS)。次要终点包括客观缓解率(ORR)和总生存期(OS)"}, {"probability": {"variance": 0.001309, "average": 0.988539, "min": 0.779965}, "location": {"width": 780, "top": 1425, "height": 51, "left": 235}, "words": "在参与该研究的患者中,389例患者(53.8%)曾接受一种以舒尼替尼为主的治疗"}, {"probability": {"variance": 2.4e-05, "average": 0.99564, "min": 0.987151}, "location": {"width": 140, "top": 1580, "height": 30, "left": 549}, "words": "第16页,共27页"}, {"probability": {"variance": 0.00388, "average": 0.961224, "min": 0.78047}, "location": {"width": 95, "top": 1614, "height": 21, "left": 251}, "words": "No:20150429"}], "language": 3}